

December 20, 2016



CV Sciences, Inc. Highlights Major League Baseball (MLB) Decision to Prohibit All New Players From Using Smokeless Tobacco

LAS VEGAS, NV -- (Marketwired) -- 12/20/16 -- CV Sciences, Inc. (OTCBB: CVSI) (the "Company", "CV Sciences", "our" or "we"), today provided comments from its management with regards to the MLB's recent ban on smokeless chewing tobacco for new players.

Beginning this upcoming season, cities that include San Francisco, Boston, and Los Angeles will ban smokeless tobacco in the big-league ballparks and other sports venues. The city councils of Chicago and New York recently approved similar prohibitions on smokeless tobacco for Wrigley Field, U.S. Cellular Field, Citi Field and Yankee Stadium.

Michael Mona, Jr., President and CEO of CV Sciences commented, "We applaud baseball's new labor agreement that prohibits all new players from using smokeless tobacco, like chew, dip and snuff. The recent death of former San Diego Padres Hall of Famer Tony Gwynn has highlighted the seriousness of the issue. Mr. Gwynn attributed his long struggle with salivary gland cancer directly to his many years of chewing tobacco. Curt Schilling, former Boston Red Sox pitcher revealed his diagnosis of oral cancer which he stated was 'without a doubt, unquestionably' due to decades of chewing tobacco. We strongly believe that highlighting these examples are critical as we at CV Sciences are addressing a massive unmet medical need in the treatment of smokeless tobacco addiction. Currently, there are no FDA-approved drugs to treat this widespread and deadly addiction. Our lead drug candidate, CVSI-007, is aimed at addressing this huge unmet need. We estimate that the current treatment market in the U.S. alone is greater than \$2 billion."

An article on baseballs' decision can be found here:

http://tobaccofreebaseball.org/content/press-release-12_1_2016/

About CV Sciences, Inc.

CV Sciences, Inc. (OTCBB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of

the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Contact:

Robert Haag

Managing Director

IRTH Communications

cvs@irthcommunications.com

866-976-4784

Source: CV Sciences, Inc.